The Bombay High Court has criticized the Maharashtra FDA for seizing ₹2.45 crore worth of stock from Cadila Pharmaceuticals Ltd without a prior hearing. The regulator has now agreed to revoke the order and follow due process. Importantly, Cadila Pharmaceuticals Ltd is an unlisted private company and is distinct from the publicly traded Zydus Lifesciences.
The Bombay High Court has directed the Maharashtra Food and Drug Administration (FDA) to be more cautious after criticizing its recent enforcement actions against Cadila Pharmaceuticals Ltd. During a hearing, the court rebuked the regulator for seizing medicines worth ₹2.45 crore across the state without granting the company a fair opportunity to be heard. The bench, presided over by Acting Chief Justice Ravindra Ghuge and Justice Gautam Ankhad, likened the FDA's approach to using a "sword to kill a mosquito," stating that the regulator appears to take drastic action before investigating the facts.
The Dispute and Resolution
The FDA had previously halted the sale and distribution of several products from Cadila Pharmaceuticals, alleging that the branding of these medicines was similar to other products. The company challenged this decision in court, arguing that the summary seizure of stock caused significant operational disruption without a prior show-cause notice. Following the court’s sharp remarks, the government counsel informed the bench that the FDA would revoke the stop-sale orders. The regulator has committed to issuing formal notices and allowing the company a proper hearing before passing any further orders. The court accepted this submission and disposed of the petition.
Important Clarification for Market Participants
Investors and market participants should note that Cadila Pharmaceuticals Ltd, the company involved in this legal dispute, is a private, unlisted entity. It is entirely separate from Zydus Lifesciences (formerly known as Cadila Healthcare), which is a publicly traded pharmaceutical company listed on the National Stock Exchange (NSE) and the Bombay Stock Exchange (BSE). There is no financial or corporate link between the two, and this legal matter has no direct impact on the stock price or financial performance of Zydus Lifesciences.
Regulatory Context and Risks
This incident highlights a broader trend of aggressive enforcement by regulatory bodies, which can create operational uncertainties for manufacturers. The High Court also noted that it has encountered similar instances where administrative authorities took drastic measures, such as shutting down warehouses or commercial establishments, without following established legal procedures. For the broader pharmaceutical sector, such regulatory actions present a compliance and operational risk. Companies must navigate these challenges by ensuring robust documentation and, when necessary, seeking legal recourse to protect their operations from summary administrative actions that can disrupt supply chains and revenue flows.